x

Posted 13 August, 2021

HealthCor Catalio Acquisition Corp. appointed Mr. Art Cohen as new CEO

Nasdaq:HYPR appointed new Chief Executive Officer Mr. Art Cohen in a 8-K filed on 13 August, 2021.


  On August 11, 2021, the board of directors of the Company (the "Board") appointed Mr. Art Cohen to serve as the Chief Executive Officer of the Company and as a director, effective immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of HealthCor Catalio Acquisition Corp.
Health Care/Life Sciences • Medical Equipment/Supplies
Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.
Market Cap
$75.6M
View Company Details
HealthCor Catalio Acquisition Corp. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers. 


On August 11, 2021, Mr. Christopher Gaulin resigned as Chief Executive Officer and a director of HealthCor Catalio Acquisition Corp., a Cayman Islands exempted company (the "Company"). Mr. Gaulin has served as Chief Executive Officer and a director since the Company's initial public offering. His resignation was not due to any disagreement with the Company. On August 11, 2021, the board of directors of the Company (the "Board") appointed Mr. Art Cohen to serve as the Chief Executive Officer of the Company and as a director, effective immediately.


Mr. Cohen, age 59, is a co-founder and portfolio manager of HealthCor Management, L.P. ("HealthCor"). Prior to HealthCor, Mr. Cohen was a portfolio manager at S.A.C. Capital Advisors, LLC ("SAC") from January 2000 through March 2005. Prior to SAC, from 1995 to 2000, Mr. Cohen was responsible for healthcare investments as a managing director at Tiger Management. Prior to Tiger Management, from 1993 to 1995, Mr. Cohen was a vice president and investment officer at JW Seligman, a vice president at Bank of New York from 1991 to 1993, and an assistant portfolio manager/analyst of the MSB Fund from 1987 to 1991. Mr. Cohen graduated from the University of Virginia in 1983 with a B.A. in commerce and received his M.B.A. in banking and finance from Hofstra University in 1986. We believe that Mr. Cohen's transactional and investing experience in the healthcare industry make him well qualified to serve on our board of directors.


There are no family relationships between Mr. Cohen and any director, executive officer, or person nominated or chosen by the Company to become an executive officer of the Company. There are no transactions between the Company and Mr. Cohen that are subject to disclosure under Item 404(a) of Regulation S-K.


Additionally, on August 11, 2021, Mr. Avi Horev resigned as a director of the Company. Mr. Horev has served as a director on the Board since the Company's initial public offering. His resignation was not due to any disagreement with the Company. On August 11, 2021, the Board appointed Mr. Benjamin Snedeker, age 45, to serve as a director on the Board. There are no transactions between the Company and Mr. Snedeker that are subject to disclosure under Item 404(a) of Regulation S-K.